Recent Articles

• Insight on Alteogen’s non-exclusive licensing deal for ALT-B4 to a top 10 global pharma
• Pharma Strategic Deal: Astellas Pharma to acquire Audentes Therapeutics for about $3 billion
• Pharma Business Development – Competency Test. Check your competency
• Case study: Novartis to acquire The Medicines Company for $9.7 billion, get hold of inclisiran, a cholesterol drug
• What is USFDA Purple Book? What it’s significance?
• USFDA approved Pfizer’s Abrilada, a biosimilar of Humira
• Pfizer’s Upjohn and Mylan merged business entity will be namea as Viatris
• Bayer and Dewpoint Therapeutics co-development deal for cardiovascular and gynecological diseases
• Sandoz to Acquire Japanese Biz of AGI
• Selumetinib NDA Submission for Neurofibromatosis Type 1 (NF1) granted Priority Review
• Insignt on Roche’s Up-to-$1.4Billion Promedior Acquisition
• Case Study: 505(b)(2) filing pathway – USFDA approval of Vumerity
• What is the significance of Clinical Hold of investigational molecules?
• US FDA places partial hold on Novartis’ AVXS-101 intrathecal study
• Zentiva to acquire CEE pharma business of Alvogen
• Insighht on USFDA approval of Trikafta
• How much is the average ideal royalty rate in pharmaceutical and biopharmaceutical business deal?
• Pharma Licensing: Explore differences between Royalty rate & Royalty base
• Takeda Divesting Select OTC and Non-core Assets of takeda to Acino
• GSK to disinvest Rabipur and Encepur – vaccine for USD 1.1 billion